Disease | non-alcoholic fatty liver disease |
Comorbidity | C0011849|diabetes mellitus |
Sentences | 37 |
PubMedID- 20625647 | Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors. |
PubMedID- 21554270 | Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease. |
PubMedID- 26573192 | Objective: to investigate the effect of body mass index (bmi) on new-onset non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
PubMedID- 23507799 | Therefore, nafld is strongly associated with type 2 diabetes mellitus and abdominal obesity. |
PubMedID- 24505484 | Conclusions: our results provide the first demonstration of a positive and independent association between nafld and avs in patients with type 2 diabetes mellitus. |
PubMedID- 23663765 | Conclusion: serum hscrp levels may be predictive of development of nafld in individuals with type 2 diabetes mellitus. |
PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
PubMedID- 24071688 | Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin. |
PubMedID- 26573193 | [relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus]. |
PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
PubMedID- 23341703 | Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. |
PubMedID- 26339423 | Prognostic value of high sensitivity c-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. |
PubMedID- 24919218 | [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus]. |
PubMedID- 23843938 | Nonalcoholic fatty liver disease (nafld) is closely associated with type 2 diabetes mellitus. |
PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
PubMedID- 26297218 | Conclusions: higher vpt associates with markers of liver fibrosis due to nafld in diabetes mellitus. |
PubMedID- 20627036 | Methods: this trial involved 51 patients of type 2 diabetes mellitus with nafld (g4 group), 50 patients of type 2 diabetes alone (g3 group), 45 patients of nafld alone (g2 group) and 42 healthy control subjects (g1 group). |
PubMedID- 22087177 | nafld is frequently associated with obesity, diabetes mellitus and the metabolic syndrome. |
PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
PubMedID- 22927782 | The aim of this study is to elucidate the effectiveness of liraglutide in nafld patients with type 2 diabetes mellitus (t2dm) compared to sitagliptin and pioglitazone. |
PubMedID- 23969900 | Increased body mass index and diabetes mellitus are associated with developing nafld and nash, which is a severe form of nafld. |
PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
PubMedID- 26201786 | nafld was strongly associated with diabetes mellitus, glucose intolerance, body mass index >/=23, low high-density lipoprotein cholesterol, hypertriglyceridemia, and hypertension. |
PubMedID- 22024083 | Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. |
PubMedID- 23760677 | Aims/hypothesis: we have previously reported a high prevalence of non-alcoholic fatty liver disease (nafld) among women with previous gestational diabetes mellitus (pgdm). |
PubMedID- 24062606 | There is a very high prevalence of nafld in individuals with type 2 diabetes mellitus. |
PubMedID- 24961024 | Gi: 52 patients diagnosed as nafld with diabetes mellitus type 2 or obesity or hyperlipedemia. |
PubMedID- 24901133 | Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. |
PubMedID- 25966055 | Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. |
PubMedID- 25243967 | [analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus]. |
PubMedID- 20604719 | Background and aims: non-alcoholic fatty liver disease (nafld) is strongly associated with obesity and diabetes mellitus. |
PubMedID- 21886908 | Type 2 diabetes mellitus-induced hyperglycemia in patients with nafld and normal lfts: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. |
PubMedID- 24961607 | The prevalence of diabetes mellitus was higher in patients with recurrent nafld (100% versus 37.5%, p < 0.01). |
Page: 1